The pharmaceutical industry was able to further increase its sales in the last quarter. The biggest players in the sector are relying on acquisitions and innovations – including the increased use of AI. However, things could get more uncomfortable for pharmaceutical companies in the US market: the future US Secretary of Health and Human Services, Rober F. Kennedy Jr., is considered a critic of the industry and has already spoken out in favor of capping drug prices.
Article on tag "Amgen"
Money tip: Are biotechnology stocks at the outset of a new upswing?
Biotechnology stocks have been back in the spotlight since the beginning of the year. Successes in research and market approvals for new drugs could provide fresh impetus. Is the sector worth a look now?
Biotechnology shares ready to stage a comeback?
In the first half of 2023, growth shares – and as such, also the biotechnology sector – came under pressure as investors were pivoting towards value shares. But the signs are changing. The possible high in interest rates in Europe and the USA could boost biotech shares again, as ERSTE STOCK BIOTEC fund manager Harald Kober explains in an interview.
Despite correction: long-term upward trend of biotech companies intact
Biotechnology shares have seen better times. Despite the most recent corrections, hopes for growth in the biotechnology sector remain very high. We spoke to Harald Kober, fund manager of ERSTE STOCK BIOTEC, about the latest developments.